Skip to main content

Table 1 Characteristics of the HEAL cohort

From: Associations between null mutations in GSTT1 and GSTM1, the GSTP1 Ile105Val polymorphism, and mortality in breast cancer survivors

 

Alla

Non-Hispanic

African American

Hispanic

 

N(%)

White N(%)

N(%)

N(%)

 

533

305

151

60

Study Site

    

Western Washington

99

83

0

2

New Mexico

283

222

0

58

Los Angeles

151

0

151

0

Body mass index (BMI) (kg/m 2 )

    

Mean (s.d)

27.8 (6.4)

26.5 (5.7)

30.7 (7.4)

27.1 (4.7)

Age (years)

    

Mean (s.d.)

57.6 (10.7)

60.6 (10.9)

52.4 (7.9)

56.2 (11.3)

Estrogen receptor (ER) status

    

Negative

109

43

52

13

Positive

375

237

88

36

Unknown

49

25

11

11

SEER b summary stage

    

Local

383

241

85

46

Regional

150

64

66

14

Treatment at diagnosis

    

Surgery

126

69

37

18

Surgery and radiotherapy

203

138

37

21

Any chemotherapy

204

98

77

21

GSTM1

    

Null Genotype

280 (52.5)

138 (45.3)

109 (72.2)

28 (46.7)

Positive Genotype

253 (47.5)

167 (54.7)

42 (27.8)

32 (53.3)

χ2 = 34.36 P<0.0001

    

GSTT1

    

Null Genotype

424 (79.6)

249 (81.6)

115 (76.2)

49 (81.7)

Positive Genotype

109 (20.4)

56 (18.4)

36 (23.8)

11 (18.3)

χ2 = 4.35 P=0.22

    

GSTP1

    

Wildtype (Ile/Ile)

223 (41.8)

137 (44.9)

53 (35.1)

27 (45.0)

Heterozygous (Ile/Val)

250 (46.9)

137 (44.9)

76 (50.3)

27 (45.0)

Homozygous (Val/Val)

60 (11.3)

31 (10.2)

22 (14.6)

6 (10.0)

χ2 = 6.16 P=0.41

    
  1. a 17 patients were described as ‘other race’; this accounts for the differences in numbers between racial/ethnic subgroups and the overall total.
  2. b Surveillance, Epidemiology and End Results (SEER).